OBI Pharma signs ADC platform licensing agreement with Novartis worth more than $2 billion

OBI Pharma has entered a global antibody-drug conjugate platform licensing agreement with Novartis carrying more than $2 billion in potential value, including a $30 million upfront payment and additional contingent milestones and royalties.
OBI Pharma announced on 13 November 2026 that it had signed a collaboration and licensing agreement granting Novartis exclusive worldwide rights to selected applications of its antibody-drug conjugate platform technologies, supporting the development of next-generation ADC therapies and novel payload approaches.
Under the agreement, OBI will receive $30 million upfront and may earn development, regulatory and commercial milestone payments that bring the total potential agreement value above $2 billion, together with tiered royalties; the majority of the headline value is contingent on future achievements, and the transaction is a technology licensing partnership rather than an acquisition of OBI Pharma or an approved drug.
Field | Content |
Article Type | Deals |
Licensor | OBI Pharma |
Licensee | Novartis |
Deal Type | Technology platform collaboration and licensing agreement |
Announcement Date | 13 November 2026 |
Agreement Status | Signed |
Licensed Technology | Antibody-drug conjugate platform technologies |
Technology Abbreviation | ADC |
Development Focus | Next-generation antibody-drug conjugates |
Additional Technology Focus | Novel ADC payload development |
Licence Scope | Selected applications of OBI Pharma's ADC platform technologies |
Licence Exclusivity | Exclusive |
Territorial Rights | Worldwide |
Upfront Payment | $30 million |
Total Potential Deal Value | More than $2 billion |
Additional Consideration | Development, regulatory and commercial milestone payments |
Royalty Structure | Tiered royalties |
Royalty Rates | Not disclosed in supplied summary |
Milestone Payment Status | Contingent on future achievements |
Guaranteed Total Deal Value | Not more than the disclosed upfront payment based on supplied information |
Therapeutic Modality | Antibody-drug conjugates |
Therapeutic Area | Oncology drug development |
Asset Acquisition | No |
Company Acquisition | No |
Approved Medicine Included | Not reported |
What Happened | OBI Pharma licensed selected ADC platform technologies to Novartis under an exclusive worldwide collaboration. |
Why It Matters | The partnership provides a major pharmaceutical company with access to emerging ADC technology while potentially generating substantial future revenue for the technology developer. |
Strategic Significance | Supports Novartis' exploration of next-generation targeted oncology therapies and validates commercial interest in OBI's platform. |
Financial Significance | The agreement includes $30 million upfront and more than $2 billion in potential total value. |
Financial Clarification | Most of the headline agreement value depends on future development, regulatory and commercial milestones. |
Transaction Clarification | This is a licensing and collaboration agreement, not an acquisition. |
Key Takeaway | Novartis has secured exclusive worldwide rights to selected OBI Pharma ADC technologies under a deal potentially worth more than $2 billion. |
What to Watch | Selection of development programmes, preclinical and clinical progress, milestone achievements and future ADC pipeline disclosures. |
Primary Source | OBI Pharma |
Primary Source URL | https://www.obipharma.com/news/signs-collaboration-and-license-agreement-with-novartis/ |
Submitted Source | The Globe and Mail |
Submitted Source URL | https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/8842040/obi-pharma-signs-adc-platform-collaboration-and-license-agreement-with-novartis/ |
Relevant Date | 13 November 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com

Commenti